157 related articles for article (PubMed ID: 8099533)
21. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study.
Wilbur DC; Barrows GH
Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877
[TBL] [Abstract][Full Text] [Related]
22. The point mutation of c-Ki-ras at codon 12 in carcinoma of the pancreatic head region and in intraductal mucin-hypersecreting neoplasm of the pancreas.
Satoh K; Sawai T; Shimosegawa T; Koizumi M; Yamazaki T; Mochizuki F; Toyota T
Int J Pancreatol; 1993 Oct; 14(2):135-43. PubMed ID: 8283077
[TBL] [Abstract][Full Text] [Related]
23. Endocrine cells in intraductal papillary-mucinous neoplasms of the pancreas. A histochemical and immunohistochemical study.
Terada T; Ohta T; Kitamura Y; Ashida K; Matsunaga Y; Kato M
Virchows Arch; 1997 Jul; 431(1):31-6. PubMed ID: 9247630
[TBL] [Abstract][Full Text] [Related]
24. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
[TBL] [Abstract][Full Text] [Related]
25. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions.
Terris B; Dubois S; Buisine MP; Sauvanet A; Ruszniewski P; Aubert JP; Porchet N; Couvelard A; Degott C; Fléjou JF
J Pathol; 2002 Aug; 197(5):632-7. PubMed ID: 12210083
[TBL] [Abstract][Full Text] [Related]
26. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
27. Intraductal papillary mucinous neoplasm of the pancreas: cytologic features predict histologic grade.
Michaels PJ; Brachtel EF; Bounds BC; Brugge WR; Pitman MB
Cancer; 2006 Jun; 108(3):163-73. PubMed ID: 16550572
[TBL] [Abstract][Full Text] [Related]
28. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
Latta EK; Tjan S; Parkes RK; O'Malley FP
Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ.
Bartkova J; Barnes DM; Millis RR; Gullick WJ
Hum Pathol; 1990 Nov; 21(11):1164-7. PubMed ID: 1977679
[TBL] [Abstract][Full Text] [Related]
30. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.
Poller DN; Galea M; Pearson D; Bell J; Gullick WJ; Elston CW; Blamey RW; Ellis IO
Breast Cancer Res Treat; 1991 Dec; 20(1):3-10. PubMed ID: 1687505
[TBL] [Abstract][Full Text] [Related]
31. C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
Lilleng R; Hagmar BM; Nesland JM
Mod Pathol; 1992 Jan; 5(1):41-7. PubMed ID: 1347423
[TBL] [Abstract][Full Text] [Related]
32. Sialylated MUC1 mucin expression in normal pancreas, benign pancreatic lesions, and pancreatic ductal adenocarcinoma.
Masaki Y; Oka M; Ogura Y; Ueno T; Nishihara K; Tangoku A; Takahashi M; Yamamoto M; Irimura T
Hepatogastroenterology; 1999; 46(28):2240-5. PubMed ID: 10521973
[TBL] [Abstract][Full Text] [Related]
33. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
[TBL] [Abstract][Full Text] [Related]
34. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
35. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas.
Iacobuzio-Donahue CA; Klimstra DS; Adsay NV; Wilentz RE; Argani P; Sohn TA; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Am J Pathol; 2000 Sep; 157(3):755-61. PubMed ID: 10980115
[TBL] [Abstract][Full Text] [Related]
36. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
37. A case of intraductal papillary tumor of pancreas associated with mucinous ductal ectasia.
Baek IS; Jeong AC; Lee SB; Choi WG; Kim JW; Kwon SY; Kim KI; Choi KW; Chang HJ
Korean J Intern Med; 1997 Jan; 12(1):100-4. PubMed ID: 9159048
[TBL] [Abstract][Full Text] [Related]
38. S100P is a novel marker to identify intraductal papillary mucinous neoplasms.
Nakata K; Nagai E; Ohuchida K; Hayashi A; Miyasaka Y; Aishima S; Oda Y; Mizumoto K; Tanaka M; Tsuneyoshi M
Hum Pathol; 2010 Jun; 41(6):824-31. PubMed ID: 20153506
[TBL] [Abstract][Full Text] [Related]
39. [Intraductal papillary mucinous neoplasm of pancreas: a clinicopathologic and immunohistochemical study of 19 cases].
Huo Z; Yang D; Chang XY; Wan JW; Chen J
Zhonghua Bing Li Xue Za Zhi; 2008 Oct; 37(10):670-5. PubMed ID: 19094485
[TBL] [Abstract][Full Text] [Related]
40. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
Ban S; Naitoh Y; Mino-Kenudson M; Sakurai T; Kuroda M; Koyama I; Lauwers GY; Shimizu M
Am J Surg Pathol; 2006 Dec; 30(12):1561-9. PubMed ID: 17122512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
